Obinutuzumab Clinical Trials
68 recruitingDrug
Phase 247Phase 116Phase 39Not Applicable1
Showing 1–20 of 68 trials
Recruiting
Phase 2
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
University of California, San Francisco30 enrolled3 locationsNCT06252675
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
National Cancer Institute (NCI)247 enrolled631 locationsNCT04269902
Recruiting
Phase 2
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma (MCL)
The First Affiliated Hospital with Nanjing Medical University39 enrolled2 locationsNCT07719556
Recruiting
Phase 1Phase 2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
City of Hope Medical Center50 enrolled3 locationsNCT05861050
Recruiting
Phase 2
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital80 enrolled2 locationsNCT06849713
Recruiting
Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche100 enrolled53 locationsNCT06806033
Recruiting
Phase 1Phase 2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 2
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
M.D. Anderson Cancer Center168 enrolled1 locationNCT04169737
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled86 locationsNCT06649812
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 2
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI)20 enrolled9 locationsNCT07003295
Recruiting
Phase 2
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Lymphoma, Mantle-Cell
The Lymphoma Academic Research Organisation100 enrolled16 locationsNCT06558604
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled187 locationsNCT06943872
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled266 locationsNCT06191744
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lymphoma
Hoffmann-La Roche50 enrolled18 locationsNCT06624085
Recruiting
Phase 1Phase 2
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mature B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche65 enrolled30 locationsNCT05533775
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled77 locationsNCT06084936
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
Hoffmann-La Roche40 enrolled42 locationsNCT05039619
Recruiting
Phase 2
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mayo Clinic120 enrolled3 locationsNCT03516617